Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor

BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice

(2012) F Ke et al.   CELL DEATH AND DIFFERENTIATION

Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol

(2012) L. Alinari et al.   CLINICAL CANCER RESEARCH

Omacetaxine as an Anticancer Therapeutic: What is Old is New Again

(2011) Meir Wetzler et al.   CURRENT PHARMACEUTICAL DESIGN

Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1

(2011) Ben A. Croker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim

(2010) L. Happo et al.   BLOOD

Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia

(2010) R. Chen et al.   BLOOD

Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi

(2010) Johannes Zuber et al.   NATURE BIOTECHNOLOGY

A mammalian functional-genetic approach to characterizing cancer therapeutics

(2010) Hai Jiang et al.   Nature Chemical Biology

BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs

(2010) E. M. Carrington et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo

(2009) David M. Lucas et al.   BLOOD

Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function

(2009) S. M. Schoenwaelder et al.   BLOOD

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

(2009) Alfonso Quintás-Cardama et al.   CANCER

Inhibitors of translation initiation as cancer therapeutics

(2009) Lisa Lindqvist et al.   Future Medicinal Chemistry

Total Synthesis of the Potent Anticancer Aglaia Metabolites (−)-Silvestrol and (−)-Episilvestrol and the Active Analogue (−)-4′-Desmethoxyepisilvestrol

(2009) Tim E. Adams et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia

(2009) K D Mason et al.   LEUKEMIA

Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells

(2009) Regina Cencic et al.   LEUKEMIA RESEARCH

XIAP discriminates between type I and type II FAS-induced apoptosis

(2009) Philipp J. Jost et al.   NATURE

Altering Chemosensitivity by Modulating Translation Elongation

(2009) Francis Robert et al.   PLoS One

Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol

(2009) Regina Cencic et al.   PLoS One

Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and β-catenin

(2008) Junya Kuroda et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation

(2008) Erinna F. Lee et al.   JOURNAL OF CELL BIOLOGY